Cancer vaccine therapy using epitope peptide from KIF20A restricted to HLA-A*24 in patients with pancreatic cancer refractory to standard therapy (Phase I/II study)

Cancer vaccine therapy using epitope peptide from KIF20A restricted to HLA-A*24 in patients with pancreatic cancer refractory to standard therapy (Phase I/II study) - Cancer vaccine therapy using epitope peptide from KIF20A restricted to HLA-A*24 in patients with pancreatic cancer refractory to standard therapy (Phase I/II study)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004919

Enrollment

Registered

2011-01-20

Start date

2009-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

peptide vaccination

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients who have unresectable / recurrent pancreatic cancer to be refractory to standard therapy or unable to continue standard therapy due to side effect 2.obtains lesion which can be evaluated by RECIST 3. Performance status (ECOG) of the patients are 0-2 4.Age between 20 to 85 5.Patients who can expect the survival of two months or more 6.Patients who have undergone operation, and recovered the influence by surgery. Or two weeks or more have passed since pre-medical treatment 7. WBC count more than 3000/mm3(or neutrophil count more than 1000/mm3), less than 15000/mm3. Plt count more than 75000/mm3. AST and ALT less than 150IU/L. T-Bil less than 3.0mg/dl Creatinine less than 2.0mg/dl 8.Able and willing to give valid written informed concent

Exclusion criteria

Exclusion criteria: 1.Pregnancy 2.Lactation 3.Patients having will of pregnancy. 4.Patients have uncontrollable severe infectional diseases. 5.Patients who are treated with steroid or immunotherapy during clinical trial. 6.Patients have uncontrollable associated cancer. 7.Patients who have non-recovered injury. 8.Patients judged inappropriated by doctors.

Design outcomes

Primary

Measure	Time frame
1.Safety and adverse effect 2.Antitumor effect	—

Secondary

Measure	Time frame
1.Immunological response Peptide specific CTL response in vitro Antigen cascade 2.Clinical efficacy Overall survival Progression free survival Median survival time	—

Countries

Japan

Contacts

Public ContactShingo Asahara

Chiba Tokushukai Hospital Internal medicine

s.asahara@chibatoku.or.jp047-466-7111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026